Therapy Areas
Latest News
Partner Therapeutics' BIZENGRI receives FDA Commissioner's National Priority Voucher for NRG1 fusion-positive cholangiocarcinoma
7 May 2026 - Biotechnology company Partner Therapeutics Inc (PTx) announced on Wednesday that the US Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) pilot program voucher for BIZENGRI (zenocutuzum...
Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma
7 May 2026 - Clinical-stage biotechnology company Diakonos Oncology Corp announced on Wednesday that the US Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 (dubodencel), its first-in-class, patient-derived double-load...
Racura Oncology identifies mechanism of action for (E,E)-bisantrene
...
Bayer to acquire Perfuse Therapeutics in USD2.45bn deal to expand ophthalmology pipeline
6 May 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) announced on Wednesday that it has agreed to fully acquire Perfuse Therapeutics Inc, strengthening its pharmaceutical pipeline and reinforcing its strategic ...
ZYUS Life Sciences receives second US pain management patent
6 May 2026 - Canada-based ZYUS Life Sciences Corporation (TSXV:ZYUS), a clinical-stage life sciences company focused on the development and commercialisation of novel non-opioid drug candidates for pain management, announced on Tuesday that the Unite...
Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital
6 May 2026 - Citius Oncology Inc (Nasdaq:CTOR), a specialty biopharmaceutical company focused on the development and commercialisation of novel targeted oncology therapies, announced on Tuesday that it has entered into a senior secured term loan cred...
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
5 May 2026 - US life sciences company Lunai Bioworks Inc (NASDAQ:LNAI) announced on Monday the completion of a USD20m preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the company's central nerv...